[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440187":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":50,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Imperial College London","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A",null,"Patients started acutely on high dose prednisolone (\\>30mg for any inflammatory condition)",[13],"Other: No intervention - prednisolone is taken as part if routine clinical care.",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B","Patients on longer term anti-inflammatory doses of prednisolone to treat any medical condition warranting their use, including post COVID.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group C","Patients receiving multiple high doses of methylprednisolone or dexamethasone in association with oral prednisolone.",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"No intervention - prednisolone is taken as part if routine clinical care.","Prednisolone given orally prior to taking timed samples for levels",[9,15,19],[28],{"name":29,"affiliation":5,"role":30},"Karim Meeran, MBBS BSc MD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Katharine Lazarus, MBChB MRCP","CONTACT","07555717544","imperial.steroids@nhs.net",[38],{"facility":39,"status":40,"city":41,"state":10,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":10},"Imperial College Healthcare NHS Trust","RECRUITING","London","United Kingdom","UK",{"type":45,"coordinates":46},"Point",[47,48],-0.12574,51.50853,{"lat":48,"lon":47},{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100440187","evaluation-of-high-dose-prednisolone-pharmacokinetics-in-the-acute-and-chronic-setting-100440187",false,"NCT05012033","Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting","EHD-Pred PK","Inclusion Criteria:\n\n* Aged 18 - 75 years\n* Male or female\n* Participants who are otherwise healthy enough to participate, as determined by pre-study medical history\n* Participants who are able and willing to give written informed consent to participate in the study\n* Group A only: Patients requiring acute (\\\u003C5 days) high dose (minimum 30mg) oral prednisolone therapy for antiinflammatory purposes in either an inpatient or outpatient setting.\n* Group B only: Minimum of 1 month duration of high dose prednisolone (\\>30mg) if in the chronic use group.\n* Group C only: Patients started on high dose methylprednisolone (\\>3 day course) or prolonged courses of dexamethasone.\n\nExclusion Criteria:\n\n* Participants with a diagnosis of Type 1 or Type 2 diabetes mellitus.\n* Unable to give informed consent.\n* Taking supplements or herbal medications that the participant is unwilling or unable to stop prior to and during the study period e.g. St John's Wort (may decrease prednisolone levels), Cat's claw, Echinacea (immunomodulatory properties).\n* Currently taking medications that alter CYP3A4 metabolism of glucocorticoids that the participant is unwilling or unable to stop prior to and during the study period e.g. phenytoin, phenobarbital, rifampicin, rifabutin, carbamazepine, primidone, aminogluethimide, itraconazole, ketoconazole, ciclosporin or ritonavir.\n* Pregnancy. Females of child-bearing age will be asked to provide a urine sample for a pregnancy test at each visit.\n* History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or compromise the safety of the participant.","ALL","18 Years","75 Years",{"count":63,"type":64},120,"ESTIMATED","OBSERVATIONAL","This is a pilot study to investigate serum prednisolone profiles in:\n\n* Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting.\n* Patients stepping up from or down to prednisolone therapy in association with a course of high dose methyl-prednisolone or dexamethasone.\n\nThe study will comprise 3 groups, including those started on high doses of prednisolone acutely in an inpatient or outpatient setting, participants on chronically high doses, and those receiving a several week course of high dose methylprednisolone or dexamethasone.\n\nThe study aims to measure prednisolone levels at a number of time points to investigate serum profile differences in those receiving prednisolone acutely compared with longer term steroid use. Further samples will be taken to characterise additional metabolic changes.",[68,69,70,71,72],"Thyroid Eye Disease","Vasculitis","COPD Exacerbation Acute","Asthma","Inflammatory Disease","2026-03-24",{"date":75,"type":76},"2026-03-27","ACTUAL",{"date":78,"type":76},"2023-04-12",{"date":80,"type":64},"2030-12-31",{"name":5,"class":6},1]